Qiagen (QGEN) Expected to Announce Earnings on Tuesday

Key Points

• QIAGEN (QGEN) is set to announce its Q2 2025 earnings on August 5th, with analysts predicting earnings of $0.60 per share and revenue of $523.97 million.
• The company reported a quarterly EPS of $0.55 in May, exceeding estimates and marking a 5.2% revenue increase year-over-year.
• Institutional investors own 70% of QIAGEN's stock, with recent investments signaling positive confidence in the company’s performance.

Qiagen (NYSE:QGEN - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.60 per share and revenue of $523.97 million for the quarter.

Qiagen (NYSE:QGEN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.50 by $0.05. The firm had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a net margin of 4.68% and a return on equity of 14.61%. The business's quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the company posted $0.44 EPS. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Stock Up 0.4%

QGEN stock traded up $0.20 during mid-day trading on Friday, hitting $49.54. 683,486 shares of the company were exchanged, compared to its average volume of 1,366,135. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.83 and a current ratio of 3.37. The firm has a market cap of $11.01 billion, a P/E ratio of 124.38, a P/E/G ratio of 2.57 and a beta of 0.68. The firm's 50 day simple moving average is $47.39 and its 200 day simple moving average is $43.39. Qiagen has a 1-year low of $37.63 and a 1-year high of $51.88.

Qiagen Dividend Announcement

The firm also recently declared a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were paid a dividend of $0.25 per share. This represents a dividend yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. Qiagen's dividend payout ratio (DPR) is currently 62.50%.

Institutional Investors Weigh In On Qiagen

An institutional investor recently bought a new position in Qiagen stock. United Services Automobile Association bought a new position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,946 shares of the company's stock, valued at approximately $239,000. Institutional investors and hedge funds own 70.00% of the company's stock.

Wall Street Analysts Forecast Growth

QGEN has been the subject of several research reports. Redburn Atlantic cut shares of Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Barclays initiated coverage on shares of Qiagen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price for the company. Bank of America raised their target price on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Robert W. Baird raised their target price on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Finally, Wall Street Zen cut shares of Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 26th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $49.40.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.